Sun Pharmaceutical Industries Limited (SUNPHARMA) — Announcement
Sun Pharmaceutical announced it will acquire 100% of Innovcare Lifesciences Private Limited for approximately ₹271.2 crores in cash, targeting completion by 31 July 2026. The deal aims to expand Sun Pharma's product portfolio through Innovcare's marketing and distribution network in India, with no regulatory approvals required. The acquisition price represents a strategic investment to strengthen market reach.
About Sun Pharmaceutical Industries Limited (SUNPHARMA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Recent Announcements from Sun Pharmaceutical Industries Limited
-
Announcement — 7 July 2026
Sun Pharmaceutical Industries Limited presented its FY26 investor outlook, highlighting Rs 582.2 Bn revenue, 27.1% EBITDA margin, and 18.8% net margin... -
share transfer — 6 July 2026
Sun Pharmaceutical Industries Limited received a confirmation certificate from MUFG Intime India Private Limited, its share transfer agent, confirming... -
Financial Results — 25 June 2026
Sun Pharmaceutical announced that its trading window for share transactions will close on 1 July 2026 and remain closed until 48 hours after the unaud... -
Announcement — 14 June 2026
Sun Pharmaceutical announced that Independent Director Gautam Doshi was arrested, but the matter is unrelated to the company and no operational or boa... -
🔴 Corporate Action — 11 June 2026
Sun Pharmaceutical announced its 34th Annual General Meeting on 31 July 2026 and set 07 July 2026 as the record date for a final dividend of ₹5 per sh...
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when SUNPHARMA files new disclosures
Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUNPHARMA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research